The benefits of antiretroviral therapy (ART) to HIV-infected patients are significant. However, ART interruption is coupled with a rapid rebound in plasma viremia. This rebound signifies the ultimate challenge surrounding ART - its inability to completely eradicate HIV. Understanding the mechanisms by which the virus is able to persist in the face of ART is necessary in order to identify strategies that may interrupt viral persistence and ultimately lead to virus eradication. There is a definite need for the implementation of in vivo models where these mechanisms can be elucidated and induction/eradication interventions aimed at virus eradication can be evaluated. Novel humanized mice (bone marrow-liver-thymus or BLT mice) developed in our laboratory could serve effectively in this capacity. Humanized BLT mice exhibit systemic reconstitution (including in the gut and vaginal mucosa) with a complete and functional human immune system. The functionality and usefulness of BLT mice in the study of HIV persistence and eradication will become evident when the following aims are completed, wherein the parameters of viral persistence will be established and novel eradication approaches will be tested. The long-term goal of our project is to develop and implement an in vivo animal model in which novel protocols for HIV-1 eradication can be evaluated. This project will first compare different drug regimens aimed at establishing durable suppression of viremia in humanized BLT mice to allow the detailed study of persistence and latency. We will then establish the sites of residual virus infection that persist despite ART. After the establishment of this model, this project will evaluate the effect of novel reagents to disrupt latency with the ultimate long-term goal of establishing virus eradication. Our goals will be achieved by pursuing the following specific aims:
Specific Aim 1 : To establish an optimal drug regimen for the durable suppression of viremia in humanized BLT mice.
Specific Aim 2 : To characterize the nature and the anatomical location of viral reservoirs which persist in BLT mice undergoing ART.
Specific Aim 3 : To characterize the effect of select induction therapeutic interventions for their ability to eradicate virus from infected BLT mice, by significantly delaying or preventing rebound after discontinuation of antiretroviral therapy. HIV eradication is a daunting task that has proven to be extremely difficult to achieve in patients. The significance of this project rests on its goal: to develop and implement a novel in vivo model in which eradication approaches aimed at the development of a potential

Public Health Relevance

The research proposed in this application is innovative, in our opinion, because it represents a new and substantially different way of addressing a most important step in the discovery process towards a cure for HIV/AIDS: the development of validated in vivo systems for the evaluation of HIV eradication strategies. In essence, our approach of developing the humanized BLT model to study HIV latency and eradication represents an important departure from the status quo in the field with the significant potential of enabling new opportunities for the translation of laboratory observations into clinical implementation.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-JBS-A)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Chapel Hill
United States
Zip Code
White, Cory H; Beliakova-Bethell, Nadejda; Lada, Steven M et al. (2018) Transcriptional Modulation of Human Endogenous Retroviruses in Primary CD4+ T Cells Following Vorinostat Treatment. Front Immunol 9:603
Chaillon, Antoine; Gianella, Sara; Lada, Steven M et al. (2018) Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc. J Virol 92:
Jiang, Guochun; Nguyen, Don; Archin, Nancie M et al. (2018) HIV latency is reversed by ACSS2-driven histone crotonylation. J Clin Invest 128:1190-1198
Dubé, Karine; Dee, Lynda; Evans, David et al. (2018) Perceptions of Equipoise, Risk-Benefit Ratios, and ""Otherwise Healthy Volunteers"" in the Context of Early-Phase HIV Cure Research in the United States: A Qualitative Inquiry. J Empir Res Hum Res Ethics 13:3-17
Prakash, Katya; Gianella, Sara; Dubé, Karine et al. (2018) Willingness to participate in HIV research at the end of life (EOL). PLoS One 13:e0199670
Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :
Honeycutt, Jenna B; Liao, Baolin; Nixon, Christopher C et al. (2018) T cells establish and maintain CNS viral infection in HIV-infected humanized mice. J Clin Invest 128:2862-2876
Power, Jennifer; Westle, Andrew; Dowsett, Gary W et al. (2018) Perceptions of HIV cure research among people living with HIV in Australia. PLoS One 13:e0202647
Marsden, Matthew D; Wu, Xiaomeng; Navab, Sara M et al. (2018) Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents. Virology 520:83-93
Beliakova-Bethell, Nadejda; Hezareh, Marjan; Wong, Joseph K et al. (2017) Relative efficacy of T cell stimuli as inducers of productive HIV-1 replication in latently infected CD4 lymphocytes from patients on suppressive cART. Virology 508:127-133

Showing the most recent 10 out of 221 publications